Neuropeptides: opportunities for drug discovery
暂无分享,去创建一个
[1] W. Rostène,et al. Nonpeptide antagonists of neuropeptide receptors: tools for research and therapy. , 1997, Trends in pharmacological sciences.
[2] L. Muglia,et al. Corticotropin-releasing hormone deficiency reveals major fetal but not adult glucocorticoid need , 1995, Nature.
[3] T. Hökfelt,et al. Galanin and spinal nociceptive mechanisms: recent advances and therapeutic implications , 2000, Neuropeptides.
[4] Eric R. Kandel,et al. Identification of a Signaling Network in Lateral Nucleus of Amygdala Important for Inhibiting Memory Specifically Related to Learned Fear , 2002, Cell.
[5] J. Hohmann,et al. Pediatrics, and , 2022 .
[6] Marc Parmentier,et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor , 1995, Nature.
[7] N. Rothwell,et al. Hypothalamic control of feeding , 1999, Current Opinion in Neurobiology.
[8] Ji-Sheng Han,et al. Acupuncture: neuropeptide release produced by electrical stimulation of different frequencies , 2003, Trends in Neurosciences.
[9] K. Fuxe,et al. Increased density of galanin binding sites in the dorsal raphe in a genetic rat model of depression , 2002, Neuroscience Letters.
[10] N. Ramsey,et al. Endogenous opioids and reward. , 2000, European journal of pharmacology.
[11] J. Halaas,et al. Leptin and the regulation of body weight in mammals , 1998, Nature.
[12] P. Mantyh,et al. Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor. , 1997, Science.
[13] Thomas R Insel,et al. Neuropeptides and the evolution of social behavior , 2000, Current Opinion in Neurobiology.
[14] Neurobiology: Fear thou not , 2003, Nature.
[15] C. Nemeroff. New directions in the development of antidepressants: the interface of neurobiology and psychiatry , 2002, Human psychopharmacology.
[16] G. Siggins,et al. Somatostatin depresses excitatory but not inhibitory neurotransmission in rat CA1 hippocampus. , 1997, Journal of neurophysiology.
[17] C. Nemeroff. Psychopharmacology of affective disorders in the 21st century. , 1998, Biological psychiatry.
[18] H. Grill,et al. The Neuroanatomical Axis for Control of Energy Balance , 2002, Frontiers in Neuroendocrinology.
[19] T. Hökfelt,et al. Hypothalamic and vagal neuropeptide circuitries regulating food intake , 2001, Physiology & Behavior.
[20] S. Nakanishi,et al. The protein-coding sequence of the bovine ACTH-β-LPH precursor gene is split near the signal peptide region , 1980, Nature.
[21] A. Simon,et al. Deletion of CCK2 Receptor in Mice Results in an Upregulation of the Endogenous Opioid System , 2002, The Journal of Neuroscience.
[22] T. Taniwaki,et al. Heterogeneity of expression of neuropeptide genes by astrocytes: functional implications. , 1994, Perspectives on developmental neurobiology.
[23] Emmanuel Mignot,et al. The Sleep Disorder Canine Narcolepsy Is Caused by a Mutation in the Hypocretin (Orexin) Receptor 2 Gene , 1999, Cell.
[24] R Guillemin,et al. Peptides in the brain: the new endocrinology of the neuron. , 1978, Science.
[25] M. Kuhar,et al. CART peptides: novel addiction- and feeding-related neuropeptides , 1999, Trends in Neurosciences.
[26] D. Naber,et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. , 2003, Archives of general psychiatry.
[27] B. Roques,et al. Dual inhibitors of enkephalin-degrading enzymes (neutral endopeptidase 24.11 and aminopeptidase N) as potential new medications in the management of pain and opioid addiction. , 1995, NIDA research monograph.
[28] F. Marshall,et al. RAMPs: accessory proteins for seven transmembrane domain receptors. , 1999, Trends in pharmacological sciences.
[29] J. Stewart,et al. Role of Tachykinins in the Host Response to Murine Gammaherpesvirus Infection , 2001, Journal of Virology.
[30] John C. Eccles,et al. Chapter 1 Chemical transmission and Dale's principle , 1986 .
[31] D. Grandy,et al. Orphanin FQ: A Neuropeptide That Activates an Opioidlike G Protein-Coupled Receptor , 1995, Science.
[32] G. Sperk,et al. Neuropeptide Y: emerging evidence for a functional role in seizure modulation , 1999, Trends in Neurosciences.
[33] T. Hökfelt,et al. The participation of galanin in pain processing at the spinal level. , 2002, Trends in pharmacological sciences.
[34] B. Roos,et al. Identification of a protein that confers calcitonin gene-related peptide responsiveness to oocytes by using a cystic fibrosis transmembrane conductance regulator assay. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[35] F. Lembeck. Zur Frage der zentralen Übertragung afferenter Impulse , 2004, Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie.
[36] Michel Bouvier,et al. Oligomerization of G-protein-coupled transmitter receptors , 2001, Nature Reviews Neuroscience.
[37] T. Theoharides. Mast cells and stress--a psychoneuroimmunological perspective. , 2002, Journal of clinical psychopharmacology.
[38] T. Hökfelt,et al. Suppressed kindling epileptogenesis in mice with ectopic overexpression of galanin , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[39] B. Rounsaville,et al. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. , 1992, Archives of general psychiatry.
[40] D. Banville,et al. Proenkephalin A gene products activate a new family of sensory neuron–specific GPCRs , 2002, Nature Neuroscience.
[41] P. Greengard. The neurobiology of slow synaptic transmission. , 2001, Science.
[42] R. Palmiter,et al. Knock-Out Mice Reveal a Critical Antiepileptic Role for Neuropeptide Y , 1997, The Journal of Neuroscience.
[43] E. Kandel. The Molecular Biology of Memory Storage: A Dialogue Between Genes and Synapses , 2001, Science.
[44] W. Colmers,et al. Effects of neuropeptide Y on the electrical properties of neurons , 1994, Trends in Neurosciences.
[45] Q. Pittman,et al. Talking back: dendritic neurotransmitter release , 2003, Trends in Neurosciences.
[46] Clifford B. Saper,et al. Unraveling the central nervous system pathways underlying responses to leptin , 1998, Nature Neuroscience.
[47] J. Lauterborn,et al. Focal hippocampal lesions induce seizures and long-lasting changes in mossy fiber enkephalin and CCK immunoreactivity , 1988, Peptides.
[48] T. Hökfelt,et al. Serotonin and substance P co-exist in dorsal raphe neurons of the human brain. , 1999, Neuroreport.
[49] D. Payan,et al. Delineation of the endocytic pathway of substance P and its seven-transmembrane domain NK1 receptor. , 1995, Molecular biology of the cell.
[50] K. Kangawa,et al. Ghrelin and the regulation of food intake and energy balance. , 2002, Molecular interventions.
[51] G. Cottrell. The first peptide-gated ion channel. , 1997, The Journal of experimental biology.
[52] O. Civelli,et al. Novel neurotransmitters as natural ligands of orphan G-protein-coupled receptors , 2001, Trends in Neurosciences.
[53] G. Coukos,et al. Corticotropin-releasing hormone promotes blastocyst implantation and early maternal tolerance , 2001, Nature Immunology.
[54] Jon T. Willie,et al. To eat or to sleep? Orexin in the regulation of feeding and wakefulness. , 2001, Annual review of neuroscience.
[55] M. Kramer. Clinical update: substance P antagonists in patients with major depression , 2002, European Psychiatry.
[56] J. P. Schwartz. Neurotransmitters as neurotrophic factors: a new set of functions. , 1992, International review of neurobiology.
[57] A. Alterman,et al. Naltrexone in the treatment of alcohol dependence. , 1992, Archives of general psychiatry.
[58] Michael Costigan,et al. Replicate high-density rat genome oligonucleotide microarrays reveal hundreds of regulated genes in the dorsal root ganglion after peripheral nerve injury. , 2002, BMC Neuroscience.
[59] B. Mellström,et al. Protein Kinase A-Dependent Derepression of the Human Prodynorphin Gene via Differential Binding to an Intragenic Silencer Element , 1998, Molecular and Cellular Biology.
[60] S. Leibowitz. Brain peptides and obesity: pharmacologic treatment. , 1995, Obesity research.
[61] M Morfis,et al. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. , 1999, Molecular pharmacology.
[62] D. Wied. Behavioral pharmacology of neuropeptides related to melanocortins and the neurohypophyseal hormones. , 1999 .
[63] E. Butelman,et al. Pharmacotherapy of addictions , 2002, Nature Reviews Drug Discovery.
[64] G. Griebel,et al. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[65] S. Iversen,et al. The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. , 1990, European journal of pharmacology.
[66] J. Drews. Drug discovery: a historical perspective. , 2000, Science.
[67] M. Lazdunski,et al. Cloning of the amiloride-sensitive FMRFamide peptide-gated sodium channel , 1995, Nature.
[68] C. Wahlestedt,et al. Expression of the novel galanin receptor subtype GALR2 in the adult rat CNS: Distinct distribution from GALR1 , 1999, The Journal of comparative neurology.
[69] Y. Hurd,et al. Reduced neuropeptide Y mRNA expression in the prefrontal cortex of subjects with bipolar disorder. , 1999, Neuroreport.
[70] P. Bolton,et al. Autism and multiple exostoses associated with an X;8 translocation occurring within the GRPR gene and 3' to the SDC2 gene. , 1997, Human molecular genetics.
[71] J. Olesen,et al. Cgrp May Play A Causative Role in Migraine , 2002, Cephalalgia : an international journal of headache.
[72] T. Moran,et al. Cholecystokinin and satiety: current perspectives. , 2000, Nutrition.
[73] R. Palmiter,et al. Ethanol consumption and resistance are inversely related to neuropeptide Y levels , 1998, Nature.
[74] E. B. Souza. Corticotropin-releasing factor receptors: Physiology, pharmacology, biochemistry and role in central nervous system and immune disorders , 1995, Psychoneuroendocrinology.
[75] T. Hökfelt,et al. Hypothalamic neurohistochemistry of the murine anorexia (anx/anx) mutation: Altered processing of neuropeptide Y in the arcuate nucleus , 1997, The Journal of comparative neurology.
[76] Sebastiaan Overeem,et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains , 2000, Nature Medicine.
[77] K. Blennow,et al. Differences in the neuropeptide Y-like immunoreactivity of the plasma and platelets of human volunteers and depressed patients , 1996, Peptides.
[78] F. Strand,et al. Neuropeptide hormones as neurotrophic factors. , 1991, Physiological reviews.
[79] T. Hökfelt,et al. Expression and localization of gastrin messenger RNA and peptide in spermatogenic cells. , 1990, The Journal of clinical investigation.
[80] S. Hunt,et al. Endogenously produced substance P contributes to lymphocyte proliferation induced by dendritic cells and direct TCR ligation , 1999 .
[81] S. Nakanishi,et al. cDNA eloping of bovine substance-K receptor through oocyte expression system , 1987, Nature.
[82] I. Whishaw,et al. DREAM Is a Critical Transcriptional Repressor for Pain Modulation , 2002, Cell.
[83] A. Schally. Aspects of hypothalamic regulation of the pituitary gland. , 1978, Science.
[84] J. Sutcliffe,et al. The hypocretins: Setting the arousal threshold , 2002, Nature Reviews Neuroscience.
[85] J. Roberts,et al. Characterization of a common precursor to corticotropin and beta-lipotropin: identification of beta-lipotropin peptides and their arrangement relative to corticotropin in the precursor synthesized in a cell-free system. , 1977, Proceedings of the National Academy of Sciences of the United States of America.
[86] Robert J. Lefkowitz,et al. Classical and new roles of β-arrestins in the regulation of G-PROTEIN-COUPLED receptors , 2001, Nature Reviews Neuroscience.
[87] J P Vincent,et al. Neurotensin and neurotensin receptors. , 1999, Trends in pharmacological sciences.
[88] Massimo Rizzi,et al. Neuropeptides-immunoreactivity and their mRNA expression in kindling: functional implications for limbic epileptogenesis , 1996, Brain Research Reviews.
[89] Masao Ito,et al. Corticotropin-Releasing Factor Plays a Permissive Role in Cerebellar Long-Term Depression , 1999, Neuron.
[90] C. Heyser,et al. Animal models of motivation for drinking in rodents with a focus on opioid receptor neuropharmacology. , 2003, Recent developments in alcoholism : an official publication of the American Medical Society on Alcoholism, the Research Society on Alcoholism, and the National Council on Alcoholism.
[91] M S Kramer,et al. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. , 1999, Trends in pharmacological sciences.
[92] C. Gall,et al. Kainic acid-induced seizures stimulate increased expression of nerve growth factor mRNA in rat hippocampus. , 1991, Brain research. Molecular brain research.
[93] Michael Aldrich,et al. Reduced Number of Hypocretin Neurons in Human Narcolepsy , 2000, Neuron.
[94] L. Swanson,et al. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing , 1983, Nature.
[95] E. Theodorsson,et al. Neuropeptide Y, neurokinin A and neurotensin in brain regions of Fawn Hooded “depressed”, wistar, and Sprague dawley rats. Effects of electroconvulsive stimuli , 1998, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[96] Stephen P. Hunt,et al. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P , 1998, Nature.
[97] Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists. , 2002, Current opinion in investigational drugs.
[98] I. Kupfermann. Functional studies of cotransmission. , 1991, Physiological reviews.
[99] R G Hill,et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. , 1998, Science.
[100] F. Holsboer,et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. , 2000, Journal of psychiatric research.
[101] D. Gerhold,et al. Chronic neuropathic pain is accompanied by global changes in gene expression and shares pathobiology with neurodegenerative diseases , 2002, Neuroscience.
[102] F E Bloom,et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[103] G. Dechant,et al. Therapy of neurodegenerative diseases using neurotrophic factors: cell biological perspective , 2002, Expert review of neurotherapeutics.
[104] R. Freidinger,et al. Nonpeptidic ligands for peptide and protein receptors. , 1999, Current opinion in chemical biology.
[105] A. Sweet-Cordero,et al. Dale's hypothesis revisited: different neuropeptides derived from a common prohormone are targeted to different processes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[106] K. Fuxe,et al. Alterations in neuropeptide Y and Y1 receptor mRNA expression in brains from an animal model of depression: region specific adaptation after fluoxetine treatment. , 1998, Brain research. Molecular brain research.
[107] L. Terenius,et al. Acquisition, Expression, and Reinstatement of Ethanol-Induced Conditioned Place Preference in Mice: Effects of Opioid Receptor-Like 1 Receptor Agonists and Naloxone , 2003, Journal of Pharmacology and Experimental Therapeutics.
[108] T. Hökfelt,et al. Activation of Delta Opioid Receptors Induces Receptor Insertion and Neuropeptide Secretion , 2003, Neuron.
[109] S. Carr,et al. Orexins and Orexin Receptors: A Family of Hypothalamic Neuropeptides and G Protein-Coupled Receptors that Regulate Feeding Behavior , 1998, Cell.
[110] A. Basbaum,et al. Resistance to excitotoxin-induced seizures and neuronal death in mice lacking the preprotachykinin A gene. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[111] T. Foroud,et al. A quantitative trait locus for alcohol consumption in selectively bred rat lines. , 1998, Alcoholism, clinical and experimental research.
[112] C. Gaveriaux-Ruff,et al. Exploring the opioid system by gene knockout , 2002, Progress in Neurobiology.
[113] A Carlsson,et al. A Paradigm Shift in Brain Research , 2001, Science.
[114] P. Ernfors,et al. Reduced antinociception and plasma extravasation in mice lacking a neuropeptide Y receptor , 2001, Nature.
[115] R. Stevenson,et al. AGTR2 Mutations in X-Linked Mental Retardation , 2002, Science.
[116] M. Palkovits,et al. Hypoalgesia in mice with a targeted deletion of the tachykinin 1 gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[117] Patrick D. Wall,et al. Pain mechanisms: A new theory , 1996 .
[118] Markus Heilig,et al. Brain Neuropeptide Υ (NPY) in Stress and Alcohol Dependence , 2002 .
[119] Walter Born,et al. An Amylin Receptor Is Revealed Following Co-Transfection of a Calcitonin Receptor with Receptor Activity Modifying Proteins-1 or -3. , 1999, Endocrinology.
[120] E. Marder,et al. The roles of co-transmission in neural network modulation , 2001, Trends in Neurosciences.
[121] T. Hökfelt,et al. Anticonvulsant activity of a nonpeptide galanin receptor agonist , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[122] H. Morris,et al. Calcitonin gene-related peptide is a potent vasodilator , 1985, Nature.
[123] Sebastiaan Overeem,et al. Hypocretin (orexin) deficiency in human narcolepsy , 2000, The Lancet.
[124] Lan Bao,et al. Identification of gene expression profile of dorsal root ganglion in the rat peripheral axotomy model of neuropathic pain , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[125] F. Holsboer,et al. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. , 1999, Journal of psychiatric research.
[126] Rachel L. Batterham,et al. Gut hormone PYY3-36 physiologically inhibits food intake , 2002, Nature.
[127] T. Renda,et al. The brain-gut-skin triangle: New peptides , 1981, Peptides.
[128] M. T. Koh,et al. Voluntary Alcohol Consumption Is Controlled via the Neuropeptide Y Y1 Receptor , 2002, The Journal of Neuroscience.
[129] S. Snyder,et al. Atypical neural messengers , 2001, Trends in Neurosciences.
[130] J M Bidlack,et al. An all D-amino acid opioid peptide with central analgesic activity from a combinatorial library. , 1994, Science.
[131] F. Holsboer,et al. Enhanced and Delayed Stress-Induced Alcohol Drinking in Mice Lacking Functional CRH1 Receptors , 2002, Science.
[132] J. Penninger,et al. Transcriptional mechanisms underlying neuropathic pain: DREAM, transcription factors and future pain management? , 2002, Expert review of neurotherapeutics.
[133] Melanie G. Lee,et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor , 1998, Nature.
[134] A. Inui. Feeding and body-weight regulation by hypothalamic neuropeptides—mediation of the actions of leptin , 1999, Trends in Neurosciences.
[135] T. Hökfelt,et al. Differential regulation of mRNAs for neuropeptide Y and its receptor subtypes in widespread areas of the rat limbic system during kindling epileptogenesis. , 1999, Brain research. Molecular brain research.
[136] J. Shine,et al. Critical role for GALR1 galanin receptor in galanin regulation of neuroendocrine function and seizure activity. , 2002, Brain research. Molecular brain research.
[137] D. Macneil,et al. Neither Agouti-Related Protein nor Neuropeptide Y Is Critically Required for the Regulation of Energy Homeostasis in Mice , 2002, Molecular and Cellular Biology.
[138] S. Woods,et al. Signals that regulate food intake and energy homeostasis. , 1998, Science.
[139] L. Maltais,et al. Anorexia, a recessive mutation causing starvation in preweanling mice. , 1984, The Journal of heredity.
[140] T. Hökfelt,et al. Altered Hippocampal Expression of Neuropeptides in Seizure‐prone GALR1 Knockout Mice , 2003, Epilepsia.
[141] G. M. Halliday,et al. Distribution, morphology and number of monoamine-synthesizing and substance P-containing neurons in the human dorsal raphe nucleus , 1991, Neuroscience.
[142] F E Bloom,et al. Overview of the most prevalent hypothalamus-specific mRNAs, as identified by directional tag PCR subtraction. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[143] E. Gibson,et al. Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability. , 1997, TIPS - Trends in Pharmacological Sciences.
[144] Jon T. Willie,et al. Narcolepsy in orexin Knockout Mice Molecular Genetics of Sleep Regulation , 1999, Cell.
[145] R. Palmiter,et al. Life without neuropeptide Y. , 1998, Recent progress in hormone research.
[146] S. Itoh,et al. Caerulein and cholecystokinin suppress β-endorphin-induced analgesia in the rat , 1982 .
[147] P. Goadsby,et al. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache , 1990, Annals of neurology.
[148] C. Epstein,et al. Primary afferent tachykinins are required to experience moderate to intense pain , 1998, Nature.
[149] L. Watkins,et al. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. , 1983, Science.
[150] H. Hashimoto,et al. Plasma neuropeptide Y in patients with major depressive disorder , 1996, Neuroscience Letters.
[151] C. Peyron,et al. The hypocretin/orexin ligand–receptor system: implications for sleep and sleep disorders , 2000, Trends in Neurosciences.